Vince Anzalone
Vice President of Investor Relations, Arrowhead Pharmaceuticals
Replay available
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) Q1 2026 earnings conference call, held 2026-02-05. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Chris Anzalone
President and Chief Executive Officer, Arrowhead Pharmaceuticals
Dan Appel
Chief Financial Officer, Arrowhead Pharmaceuticals
Mike Oles
Analyst, Morgan Stanley
Mari Raycroft
Analyst, Jefferies
Andrea Newkirk
Analyst, Goldman Sachs
Prakhar Agarwal
Analyst, Cantor Fitzgerald
Jason Gerber
Analyst, Bank of America
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Arrowhead Pharmaceuticals, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.237 Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals conference call. 00:00:04.237 -- 00:00:08.823 Without today's recorded presentation, all participants will be in a listen-only mode. 00:00:08.823 -- 00:00:12.347 After the presentation, there will be an opportunity to ask questions. 00:00:12.347 -- 00:00:17.474 I will now hand the conference over to Vince Anzalone, Vice President of Investor Relations 00:00:17.474 -- 00:00:20.699 for Arrowhead. Please go ahead, Vince. 00:00:20.699 -- 00:00:24.864 Thank you, Victor. Good afternoon. Thank you for joining us today to discuss Arrowhead's 00:00:24.864 -- 00:00:29.880 results for its fiscal 2026. First quarter ended December 31st, 2025. 00:00:29.880 -- 00:00:34.466 With us today for management are President and CEO, Dr. 00:00:34.466 -- 00:00:38.911 Chris Anzalone, who will provide an overview, Andy Davis, Senior Vice President and Head 00:00:38.911 -- 00:00:43.396 of the Global Cardio-Vetabolic Franchise, who will provide an update on commercialization 00:00:43.396 -- 00:00:48.563 activities, Dr. James Hamilton, Chief Medical Officer and Head of R&D, who will discuss 00:00:48.563 -- 00:00:53.909 our development programs, and Dan Appel, Chief Financial Officer, who will give a review 00:00:53.909 -- 00:00:58.777 of the financials. Following management's prepared remarks, we will open the call to 00:00:58.777 -- 00:01:03.404 questions. Before we begin, I would like to remind you that comments made during today's 00:01:03.404 -- 00:01:08.591 call contain certain forward-looking statements within the meaning of Section 27A 00:01:08.591 -- 00:01:13.939 of the Securities Act of 1933 and Section 21E of the Securities Exchange 00:01:13.939 -- 00:01:15.641 Act of 1934. 00:01:15.641 --...